411 related articles for article (PubMed ID: 25216638)
1. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Rudalska R; Dauch D; Longerich T; McJunkin K; Wuestefeld T; Kang TW; Hohmeyer A; Pesic M; Leibold J; von Thun A; Schirmacher P; Zuber J; Weiss KH; Powers S; Malek NP; Eilers M; Sipos B; Lowe SW; Geffers R; Laufer S; Zender L
Nat Med; 2014 Oct; 20(10):1138-46. PubMed ID: 25216638
[TBL] [Abstract][Full Text] [Related]
2. Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14.
Avila M; Berasain C
Hepatology; 2015 May; 61(5):1755-7. PubMed ID: 25677471
[No Abstract] [Full Text] [Related]
3. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
4. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
7. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
8. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
9. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
12. RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.
Li GM; Wang YG; Pan Q; Wang J; Fan JG; Sun C
Int J Clin Exp Pathol; 2014; 7(3):1085-92. PubMed ID: 24696725
[TBL] [Abstract][Full Text] [Related]
13. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Giovannini C; Baglioni M; Baron Toaldo M; Ventrucci C; D'Adamo S; Cipone M; Chieco P; Gramantieri L; Bolondi L
Oncotarget; 2013 Oct; 4(10):1618-31. PubMed ID: 24113128
[TBL] [Abstract][Full Text] [Related]
14. Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Luo L; Cai L; Luo L; Tang Z; Meng X
Mol Med Rep; 2018 Jun; 17(6):8053-8060. PubMed ID: 29693700
[TBL] [Abstract][Full Text] [Related]
15. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
17. Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Nam SW; Park KC; Yang KJ; Lee B; Kim SW
Int J Oncol; 2014 Oct; 45(4):1450-6. PubMed ID: 25017961
[TBL] [Abstract][Full Text] [Related]
18. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
20. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]